StreetInsider.com News Articles

GT Biopharma integrates AI tools to accelerate drug discovery

Mon, 01 Jun 2026 08:04:32 -0400

GT Biopharma Inc. (NASDAQ: GTBP) announced the implementation of artificial intelligence-based technologies across its drug discovery and engineering programs. The clinical-stage immuno-oncology company said the AI tools are designed to accelerate development of tumor-targeting engagers and multi-domain proteins while reducing costs.

The company uses AI-guided sequence and structural analyses to identify candidate molecules with favorable binding, stability, and developability profiles. The technology also optimizes domain orientation, linker design, and spatial architecture to enhance binding and minimize structural issues that could affect potency or manufacturability.

"We have seen a marked acceleration in our discovery productivity following recent initiatives implementing AI-based technologies, which have

GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives

Mon, 01 Jun 2026 08:00:00 -0400

Increased integration of artificial intelligence–based tools across the discovery and engineering of tumor-targeting engagers and multi-domain proteins to accelerate development while reducing developmental costs

Reduces reliance on trial-and-error experimentation, shortens development timelines, and increases likelihood that pipeline candidates demonstrate robust binding and functional activity suitable for translational advancement

GT Biopharma anticipates multiple new development candidates moving into pre-IND development in 2027, with potential targets and indications expanding beyond oncology

SAN FRANCISCO, CALIFORNIA, June 01, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused

GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives

Mon, 01 Jun 2026 08:00:00 -0400

GT Biopharma anticipates multiple new development candidates moving into pre-IND development in 2027, with potential targets and indications expanding beyond oncology

SAN FRANCISCO, CALIFORNIA, June 01, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused

Form 8-K GT Biopharma, Inc. For: May 20

Fri, 22 May 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260522/26538683.html

Form 8-K GT Biopharma, Inc. For: May 20

Fri, 22 May 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260522/26538683.html

Form 10-Q GT Biopharma, Inc. For: Mar 31

Fri, 15 May 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260515/26499784.html

Form 10-Q GT Biopharma, Inc. For: Mar 31

Fri, 15 May 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260515/26499784.html

GT Biopharma Reports First Quarter 2026 Financial Results

Fri, 15 May 2026 08:00:00 -0400

Phase 1 trial evaluating GTB-3650 TriKE® remains ongoing, with additional updates anticipated in 2H 2026

Phase 1 basket trial evaluating GTB-5550 TriKE® in multiple solid tumor types known to express B7-H3 initiated May 2026 with updates anticipated in 2H 2026 as enrollment progresses through dose escalation cohorts

Cash balance as of March 31, 2026 of approximately $9 million anticipated to provide sufficient cash runway through Q4 2026

SAN FRANCISCO, CALIFORNIA, May 15, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing

GT Biopharma Reports First Quarter 2026 Financial Results

Fri, 15 May 2026 08:00:00 -0400

Phase 1 trial evaluating GTB-3650 TriKE® remains ongoing, with additional updates anticipated in 2H 2026

Cash balance as of March 31, 2026 of approximately $9 million anticipated to provide sufficient cash runway through Q4 2026

SAN FRANCISCO, CALIFORNIA, May 15, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing

GT Biopharma Reports First Quarter 2026 Financial Results

Fri, 15 May 2026 08:00:00 -0400

Phase 1 trial evaluating GTB-3650 TriKE® remains ongoing, with additional updates anticipated in 2H 2026

Cash balance as of March 31, 2026 of approximately $9 million anticipated to provide sufficient cash runway through Q4 2026

SAN FRANCISCO, CALIFORNIA, May 15, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing

GT Biopharma Reports First Quarter 2026 Financial Results

Fri, 15 May 2026 08:00:00 -0400

Phase 1 trial evaluating GTB-3650 TriKE® remains ongoing, with additional updates anticipated in 2H 2026

Cash balance as of March 31, 2026 of approximately $9 million anticipated to provide sufficient cash runway through Q4 2026

SAN FRANCISCO, CALIFORNIA, May 15, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing

GT Biopharma Reports First Quarter 2026 Financial Results

Fri, 15 May 2026 08:00:00 -0400

Phase 1 trial evaluating GTB-3650 TriKE® remains ongoing, with additional updates anticipated in 2H 2026

Cash balance as of March 31, 2026 of approximately $9 million anticipated to provide sufficient cash runway through Q4 2026

SAN FRANCISCO, CALIFORNIA, May 15, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing

GT Biopharma Reports First Quarter 2026 Financial Results

Fri, 15 May 2026 08:00:00 -0400

Phase 1 trial evaluating GTB-3650 TriKE® remains ongoing, with additional updates anticipated in 2H 2026

Cash balance as of March 31, 2026 of approximately $9 million anticipated to provide sufficient cash runway through Q4 2026

SAN FRANCISCO, CALIFORNIA, May 15, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing

GT Biopharma Reports First Quarter 2026 Financial Results

Fri, 15 May 2026 08:00:00 -0400

Phase 1 trial evaluating GTB-3650 TriKE® remains ongoing, with additional updates anticipated in 2H 2026

Cash balance as of March 31, 2026 of approximately $9 million anticipated to provide sufficient cash runway through Q4 2026

SAN FRANCISCO, CALIFORNIA, May 15, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing

GT Biopharma Reports First Quarter 2026 Financial Results

Fri, 15 May 2026 08:00:00 -0400

Phase 1 trial evaluating GTB-3650 TriKE® remains ongoing, with additional updates anticipated in 2H 2026

Cash balance as of March 31, 2026 of approximately $9 million anticipated to provide sufficient cash runway through Q4 2026

SAN FRANCISCO, CALIFORNIA, May 15, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing

"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies

Thu, 14 May 2026 10:55:00 -0400